Laboratory Corporation of America Holdings Inc. announced the resignation of an executive of the company’s Covance Drug Development division, according to a filing with the Securities and Exchange Commission on Wednesday.
Deborah Keller, chief executive officer of the Covance Drug Development division, told the biopharma company she intends to resign on Oct. 1.
Keller is leaving her position as CEO of the division to pursue other interests, according to the Sept. 7 SEC filing. The company did not disclose any details of the other interests.
Keller became CEO of the Covance division in August 2015, succeeding Joseph Herring, who held the position for over a decade. The company did not disclose who will fill the role after Keller leaves in October.
Burlington-based LabCorp, an S&P 500 company, is a health care diagnostics company that provides end-to-end drug development support through Covance Drug Development. The company had a net revenue in excess of $8.5 billion in 2015 and employs over 50,000 personnel across the globe.
LabCorp’s shares closed Wednesday at $140.46, up $2.64, or 1.8 percent, from the opening price of the day.
Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism.
